"prognosis (5-year survival rates):"
"Bronchogenic carcinoma is a term that is frequently used as a synonym for lung cancer, but is inaccurate because lung cancers can arise in any lung component, not just the airways 17."
"prognosis (5-year survival rates):"
"Pneumonia, pleural effusion, wheeze, lymphadenopathy are not uncommon. Other symptoms may be secondary to metastases (bone, contralateral lung, brain, adrenal glands, and liver, in frequency order for NSCLC 12) or paraneoplastic syndromes (see below)."
"most common primary lung malignancy to cause paraneoplastic syndromes and SVC obstruction"
"thyroid transcription factor 1 (TTF-1): expressed in most lung cancer except squamous cell cancer"
"ALK mutation: 2-5% of NSCLC; more common in males, younger, light/never smokers, and more likely to be adenocarcinoma presenting with advanced disease 16 (see: main article)"
"SIADH causing hyponatraemia: small-cell subtype"
"PTH-related peptide (PTHrp) causing hypercalcaemia: squamous cell carcinoma"
"Treatment and prognosis vary not only with stage but also with cell type. In general, surgery, chemotherapy, and radiotherapy are offered according to the stage, resectability, operability, and functional status. Targeted treatments depend on molecular testing, e.g. ALK mutated lung cancers can be treated with ALK-inhibitors (e.g. crizotinib) 16."
"Treatment and prognosis vary not only with stage but also with cell type. In general, surgery, chemotherapy, and radiotherapy are offered according to the stage, resectability, operability, and functional status. Targeted treatments depend on molecular testing, e.g. ALK mutated lung cancers can be treated with ALK-inhibitors (e.g. crizotinib) 16."
"Lambert-Eaton myasthenia syndrome"
Expected headings
"Staging"
"Associations"
"Non-small cell carcinoma"
"Small-cell carcinoma"
"This article gives an overview of the histological subtypes, focusing on their common aspects; for more information, please refer to the articles on each subtype described below."
"ROS1 mutation: 1-2% of NSCLC 15; more common in females 14"
"ALK mutation: 2-5% of NSCLC; more common in males, younger, light/never smokers, and more likely to be adenocarcinoma presenting with advanced disease 16 (see: main article)"
"hypocalcaemia: occurs in the setting of skeletal metastases; especially associated with NSCLC 6"
"Treatment and prognosis vary not only with stage but also with cell type. In general, surgery, chemotherapy, and radiotherapy are offered according to the stage, resectability, operability, and functional status. Targeted treatments depend on molecular testing, e.g. ALK mutated lung cancers can be treated with ALK-inhibitors (e.g. crizotinib) 16."